Please ensure Javascript is enabled for purposes of website accessibility

Altria Launches New $2 Billion Stock Buyback as Q4 Sales Beat, Profits Miss

By Rich Duprey - Updated Jan 28, 2021 at 10:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tobacco company still got singed by most of the non-combustible portion of its portfolio.

Altria Group (MO 0.00%) reported its cigarette business has held up spectacularly during the COVID-19 pandemic, with fourth-quarter sales rising 5% to $6.3 billion and handily beating analyst expectations.

But the tobacco giant's investments in electronic cigarette maker Juul Labs and marijuana producer Cronos Group (CRON -0.88%) continue to weigh on performance, and adjusted earnings of $0.99 per share fell short of Wall Street's forecast of $1.02 per share.

The board of directors also announced a new $2 billion stock buyback program that it expects to complete by July.

$100 bills under a magnifying glass and stock chart

Image source: Getty Images.

Still a cloudy future

Altria CEO Billy Gifford said, "Our tobacco businesses were resilient and we made steady progress toward our 10-year vision to responsibly transition adult smokers to a noncombustible future."

It's a nice sentiment, but the noncombustible portion of its portfolio really went nowhere. Philip Morris International's (PM 0.65%) IQOS heated tobacco device, for example, is still in only three markets despite having gotten regulatory approval to sell the e-cig in the U.S. almost two years ago. 

It's possible Altria was waiting for the Food & Drug Administration to sign off on the third-generation IQOS device, which it did in December, before launching a nationwide rollout, but with other e-cig makers awaiting their own approvals, Altria is losing its first-mover advantage.

The Juul debacle is still ongoing as well, and though the device still owns over half the market, the fair value of its investment swiped a nickel from earnings per share according to generally accepted accounting principles (GAAP), while the Cronos investment cost Altria another $0.04 in EPS. 

Altria provided full-year guidance and foresees earnings growth of 3% to 6%, or $4.49 to $4.62 per share. The tobacco giant's dividend of $3.44 per share currently yields 8.2% annually. It maintains a long-term dividend payout ratio target of approximately 80% of adjusted EPS.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group, Inc. Stock Quote
Altria Group, Inc.
$51.09 (0.00%) $0.00
Philip Morris International Inc. Stock Quote
Philip Morris International Inc.
$101.15 (0.65%) $0.65
Cronos Group Stock Quote
Cronos Group
$3.39 (-0.88%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.